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Abstract
Background: Extracellular Tau is toxic for neighboring cells, and it contributes to the progression of AD. The
CX3CL1/CX3CR1 axis is an important neuron/microglia communication mechanism.
Methods: We studied Tau clearance by microglia both in vitro (microglia primary cultures treated with Cy5-Tau,
affinity chromatography to study the binding of Tau to CX3CR1, and Tau-CX3CL1 competition assays) and in vivo
(stereotaxic injection of Cy5-Tau into WT and CX3CR1−/− mice). The expression of CX3CR1, CX3CL1 and the
microglial phagocytic phenotype were studied in brain tissue samples from AD patients.
Results: Tau binding to CX3CR1 triggers the internalization of the former by microglia, whereas S396 Tau
phosphorylation decreases the binding affinity of this protein to CX3CR1. Of note, the progressive increase in the
levels of phosho-Tau occurred in parallel with an increase in CX3CR1. In addition, our studies suggest that the
phagocytic capacity of microglia in brain tissue samples from AD patients is decreased. Furthermore, the CX3CR1/
CX3CL1 axis may be impaired in late stages of the disease.
Conclusions: Our data suggest that the CX3CR1/CX3CL1 axis plays a key role in the phagocytosis of Tau by
microglia in vitro and in vivo and that it is affected as AD progresses. Taken together, our results reveal CX3CR1 as a
novel target for the clearance of extracellular Tau.
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Background
Tau is a microtubule-associated protein that plays a crit-
ical role in the pathogenesis of several related disorders
collectively known as tauopathies [1]. Alzheimer disease
(AD) is the most prevalent tauopathy and the main cause
of dementia among older adults. In this disease, intracellu-
lar Tau forms filamentous structures of aggregated and
hyperphosphorylated protein (phospho-Tau), which are
associated with neuronal death. Tau is released into the
extracellular space through physiological and pathological
mechanisms and can be toxic for neighboring cells. This
effect may contribute to the progression of a number of
neurodegenerative diseases [2, 3].
Microglia are the resident immune cells of the central
nervous system (CNS) [4, 5]. Under physiological condi-
tions, they are quiescent and scattered throughout the
CNS [6]. In response to CNS damage, microglia become
activated to exert their classic role as “scavengers”. They
proliferate, change their morphology, and phagocytose
cells and structures that may impair CNS homeostasis
[7]. These microglial functions are regulated by commu-
nication between neurons, astrocytes and microglia [8]
through cytokines, chemokines, trophic factors, and
other molecules.
One signaling pathway through which neurons and
microglia communicate is the neuronal cytokine
CX3CL1 (fractalkine) and its microglial receptor
(CX3CR1) [9]. CX3CL1 is expressed by neurons either
as a membrane-bound or a secreted ligand [10, 11]. The
binding of CX3CL1 to CX3CR1 maintains microglia in
an “off” state [12], thereby inhibiting the release of pro-
inflammatory cytokines [13, 14]. In contrast, deficiency
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of CX3CL1 or CX3CR1 leads to an increased production
of pro-inflammatory molecules [15]. While there is a
correlative link between neuroinflammation and tauopa-
thies and several studies have shown that microglia drive
Tau pathology and contribute to the spread of patho-
logical Tau [16, 17], there is little mechanistic evidence
that altered microglial activity is involved in the patho-
genesis of these diseases [18–20].
Our previous studies, among others, have demon-
strated that extracellular Tau can be taken up by micro-
glia [21, 22]; however, the precise mechanisms involved
in this process are unknown. To study these mecha-
nisms, here we used mice in which Cx3cr1 was replaced
with a cDNA encoding enhanced green fluorescent pro-
tein (EGFP) (CX3CR1−/− mice) [23]. Our results indicate
that, in the absence of CX3CR1, microglia had an altered
phagocytic response to Tau. In particular, CX3CR1 defi-
ciency was associated with impaired uptake and degrad-
ation of Tau by microglia both in vitro and in vivo.
Furthermore, our study is the first to demonstrate that
Tau binds to CX3CR1, that by doing so Tau increases its
own internalization by microglia, and that Tau competes
with the natural ligand of CX3CR1, namely CX3CL1, to
bind to this receptor. These data, together with the ob-
servation that patients with an advanced stage of AD
show an increase in the expression of the CX3CL1/
CX3CR1 axis in the hippocampus, identify CX3CR1 as a
receptor that plays a pivotal role in the regulation of Tau
phagocytosis by microglia.
Methods
Peptides
The recombinant human Tau isoform containing 2 N-
terminal inserts and 4 microtubule binding repeats
(Tau42 [24]) was isolated as described previously [25].
Purified Tau42, 1 mg/ml, was used for affinity chroma-
tography assays or was labeled with sulfoindocyanine
Cy5 dye (GE Healthcare, UK), as described previously
[21] following the manufacturer’s recommendations. As
a control for Tau specificity, Bovine serum albumin
(BSA) (1 mg/ml), was labeled with Cy5 dye following the
same protocol. The synthetic CX3CR1 peptide sequence:
DQFPESVTENFEYDDLAEAC (aa 2–21) containing the
binding region to CX3CL1, and synthetic c-terminal Tau
peptide sequence: HLSNVSSTGSIDMVDSPQLATLA
DEV (aa 407–432), containing the C-terminal fragment
of Tau with negatively charge amino acids like D and E,
were purchased from Abyntek. Full-length CX3CL1 pep-
tide was obtained from R&D Systems, USA.
Animals
CX3CR1 (KO) mice with a targeted mutation (B6.129P–
Cx3cr1tm1Litt/J) were obtained from the Jackson Labora-
tories (Bar Harbor, Maine). Two-month-old KO and
control C57Bl/6 (WT) (Harlan Laboratories, Netherlands)
mice were used for the in vivo experiments involving
stereotaxic injection of 1 mg/ml Tau-Cy5 or PBS-Cy5. Mice
were housed in a specific pathogen-free colony facility, in
accordance with European Community Guidelines (direct-
ive 86/609/EEC), and handled following European and local
animal care protocols. Animal experiments received the ap-
proval of the CBMSO’s Ethics Committee and the National
Ethics Committee (AEEC-CBMSO-62/14).
Primary cultures
Microglia were cultured from the cerebral cortices of 2-
day-old mice, as described previously [21]. These cells
were seeded onto 24-well plates (3 × 105 cells/well) with
coverslips. Adherent cells were incubated for 48 h before
being used for the experiments.
Human subjects
The use of tissue samples from the human hippocampus
was coordinated by the local Brain Bank (Banco de
Tejidos CIEN Foundation, Madrid), following national
laws and international ethical and technical guidelines on
the use of human samples for biomedical research pur-
poses. In all cases, brain tissue donation, processing, and
use for research purposes were in compliance with pub-
lished protocols (Best Practices for Repositories [26]),
which include informed consent for brain tissue donation
from living donors and the approval of the whole donation
process by an Ethics Committee. Epidemiological infor-
mation on the subjects involved in this study is included
in Table 1. Hippocampal samples were obtained post-
mortem and were post-fixed O/N in 4% PFA.
Tau internalization assay
Primary microglia cultures were treated with either Tau-
Cy5, BSA-Cy5 or vehicle (phosphate saline buffer (PBS)-
Cy5) at 1 μM for 0, 5, 30 and 60 min. In addition, micro-
glia cultures were treated with phospho-TauCy5 or
control Tau-Cy5 at 1 μM for 30 min. For the competi-
tion assay, microglia cultures were treated with CX3CL1
(5 ng / ml) for 30 min. Afterwards, 1 μM Tau-Cy5 was
added to the culture for 5 min. After treatment, cells
were washed three times with PBS in order to remove
the excess Tau attached to the membrane. Cells were
fixed with 4% paraformaldehyde in 0.1 N phosphate buf-
fer (PB) for the immunofluorescence analysis.
Tau membrane binding assay
Primary microglia cultures were plated and after 48 h
were treated with 1 μM Tau-Cy5 at for 5 min at 4 °C.
These experimental conditions allow the binding of Tau
to the surface of the cells, thereby minimizing the in-
ternalization of Tau into microglia. After treatment, cells
were washed only once with PBS. Cells were fixed with
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Table 1 Table shows epidemiological information on human brain tissue samples from the hippocampus
CODE AGE GENDER POST-MORTEM INTERVAL BRAAK-TAU DIAGNOSIS
CONTROL 1 65 MALE 3 0 Methastasis
2 52 FEMALE 6 0 Mental retardation
3 75 FEMALE 1 0 Neuropathy
4 71 MALE 5,5 0 FTD
5 78 MALE 4 0 Dyslipidemia
6 80 MALE 3 0 Neuropathy
7 43 MALE 5 0 Leukaemia
8 56 FEMALE 5 0 ALS
9 68 MALE 4 0 MSA
10 41 MALE 6 0 ALS
BRAAK-TAU I and II 11 FEMALE 6 I ALS
12 67 FEMALE 6 I ALS
13 82 MALE 5 I PD
14 73 MALE 9 I AD
15 76 MALE 3 II PD
16 73 MALE 6,5 II Vascular dementia
BRAAK-TAU III and IV 17 80 FEMALE 5 III ALS
18 85 MALE 8,5 III Dementia
19 70 FEMALE 9 III ALS
20 82 FEMALE 3,5 IV FTD
21 79 MALE 4,5 IV AD
22 62 MALE 5 IV PD
BRAAK-TAU V and VI 23 93 FEMALE 5,5 V AD
24 92 MALE 4 V AD
25 73 MALE 5 V AD
26 80 MALE 5 V AD
27 81 MALE 2,5 V AD
28 FEMALE 4 V AD
29 85 MALE 2,5 V AD
30 89 FEMALE 6 V AD
31 93 MALE 8 V AD
32 86 FEMALE ? V AD
33 82 FEMALE ? V AD
34 78 FEMALE 6,5 V AD
35 84 MALE 4 VI AD
36 91 FEMALE 3 VI AD
37 92 FEMALE ? VI AD
38 83 FEMALE 3,5 VI AD
39 87 MALE 10 VI AD
40 90 FEMALE 10 VI AD
41 89 FEMALE 4,5 VI AD
42 60 MALE 4,5 VI AD
43 55 MALE 5 VI AD
44 92 MALE 6 VI AD
45 77 MALE 9 VI AD
Control, Braak-Tau I and II, Braak-Tau III and IV, and Braak-Tau V and VI groups are shown. Information regarding code, age, gender, postmortem interval,
Braak-Tau stage and diagnosis of each sample is indicated
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4% paraformaldehyde in 0.1 N PB, and Tau bound to
microglia membrane surface was measured by immuno-
fluorescence analysis.
Microglia activation assay
Primary microglia cultures were treated with Tau-Cy5 or
vehicle PBS-Cy5 at 1 μM for 5 and 30 min. In order to
avoid the activation of the cells caused by the addition of
the new medium, the first time represented is 5 min
after treatment. Cells were washed three times with PBS
after treatment in order to remove the excess Tau at-
tached to the membrane. They were then fixed with 4%
paraformaldehyde in PB for the immunofluorescence
analysis of microglia activity using CD68 marker.
Immunocytochemistry
After treatment, cells were fixed in 4% paraformaldehyde
in PBS. Microglia were then stained with rabbit anti-
Iba1 (1:1000, Wako, Japan), mouse anti-Cy5 (1:2000, GE
Healthcare, UK) and rat anti-CD68 (1:1000, Abcam,
UK), all diluted in 1% bovine serum plus 1% Triton in
0.1 N PB. For Tau membrane binding assays, antibodies
were diluted in the same buffer without Triton. Cells
were then incubated with a donkey anti-goat IgG conju-
gated to Alexa Fluor 488, donkey anti-rat IgG conju-
gated to Alexa Fluor 555, donkey anti-mouse IgG
conjugated to Alexa Fluor 647 (1:1000), and DAPI
(Merck, USA) at 1:10,000 dilution.
Stereotaxic surgery and sacrifice
Mice were anesthetized with Isoflurane and placed in a
stereotaxic frame. Coordinates (mm) relative to the
Bregma in the anteroposterior, mediolateral, and dorso-
ventral planes were as follows: dentate gyrus (DG) of the
hippocampus [− 2.0; ±1.4; −2.2]. Next, 2 μl/DG of Tau-
Cy5 (1 mg/ml) or PBS-Cy5 solution was infused at
0.2 μl/min via a glass micropipette. After 1 and 8 weeks,
mice were fully anesthetized by means of an intraperito-
neal injection of 50 μl of pentobarbital and transcardially
perfused with 0.9% saline followed by 4% paraformalde-
hyde in PB. Brains were removed and post-fixed over-
night in the same fixative.
Immunohistochemistry
Sagittal murine brain sections were obtained on a Leica
VT1200S vibratome (50-μm thick sections). Immunohis-
tochemistry was performed as described previously [27].
For all the analyses, series of brain slices were made up
randomly of one section from every ninth. Whole series,
containing 8–10 sections, were used for the immunohis-
tochemical detection of Iba1, CX3CR, CX3CL1 and Tau.
For mice, the mouse anti-Cy5 (1:2000, GE Healthcare,
UK) and rabbit anti-Iba1 (1:500, Wako, Japan) antibodies
were used, both in 1% (v/v) bovine serum plus 1% (v/v)
triton in 1 N PB. For human tissue, the rabbit anti-
phospho-Tau S396 (p-S396) (1:500, Life Technologies,
USA), goat anti-Iba1 (1:500, Abcam, UK), goat anti-
CX3CR1 (1:500, Sigma, USA) and goat anti-CX3CL1
(1:500, R&D, USA) antibodies were used, all in 1% (v/v)
bovine serum plus 1% (v/v) Triton in 1 N PB. Primary
antibodies were incubated for 48 h at 4 °C. The follow-
ing secondary Alexa-conjugated antibodies were used at
a final concentration of 1:1000 diluted in 1% (v/v) bovine
serum plus 1% (v/v) triton in 1 N PB: donkey anti-
mouse IgG conjugated to Alexa Fluor 555 or 647; don-
key anti-rabbit IgG conjugated to Alexa Fluor 488 or
555; and donkey anti-goat IgG conjugated to Alexa Fluor
647 (Thermo Fisher,USA). Secondary antibodies were in-
cubated overnight at 4 °C. All sections were counter-
stained with DAPI at 1:5000 dilution. For human slices,
immunohistochemistry was performed as described,
adding an autofluorescence eliminator reagent
(Millipore, USA) after DAPI incubation in order to re-
move any autofluorescence of the tissue [28].
Confocal image acquisition and image analysis
Confocal stacks of images (Z-axis interval: 1 μm) were
obtained in a Zeiss LSM710 confocal microscope under
either 25X, 40X or 63X oil objectives. Images were ana-
lyzed using ImageJ Version 1.46r (National Institutes of
Health, Bethesda, MD). The JACoP plugin [29] was used
for colocalization analysis.
- Fluorescence intensity analysis: The fluorescence in-
tensity of Cy5, Iba1, phospho-tau (p-396), CX3CR1 and
CX3CL1 was determined in vivo. In order to measure
the fluorescence intensity of Cy5 staining, three confocal
images per mouse were obtained under a 40X magnifica-
tion objective in the hippocampal DG. Images were sub-
jected to a fixed threshold, and the area above the
threshold that was Cy5+ was measured. Data relative to
fluorescence intensity are thus presented as % of positive
area. To measure phospho-tau (p-S396) fluorescence in-
tensity in human tissue, three-to six images per subject
were obtained in the hippocampal region. Images were
subjected to a fixed threshold and the area above the
threshold that was p-S396+ was measured. Data relative
to fluorescence intensity are thus presented as % of posi-
tive area. In order to analyze the fluorescence intensity
of CX3CR1 and CX3CL1 staining, the area of the gran-
ule layer (GL) of the dentate gyrus (DG) was drawn on
25X confocal images. Images were subjected to a fixed
threshold and the area above the threshold that was
CX3CR1+ or CX3CL1+ was measured and then divided
by the total area of the GL. Data relative to fluorescence
intensity are thus presented as % of positive area. Three-
to-six images were obtained per mouse or subject.
- Colocalization analysis: The colocalization between
Cy5 and Iba1 was measured in vitro and in vivo (in the
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brains of stereotaxically injected mice). The colocalization
between CD68 and Iba1 was measured in vitro. For the in
vitro measurements, internalized Tau-Cy5 or Tau-Cy5 at-
tached to the membrane surface and CD68 expression were
measured by quantifying the levels of Cy5 or CD68 staining
inside, or levels of Cy5 on the surface of microglial cells.
For this purpose, the contour of individual microglial cells
was drawn in the Iba1 channel and the total area was mea-
sured on 40X magnification images. Images were subjected
to an invariant threshold and the Cy5+ or CD68+ area
above the threshold was measured and then divided by the
selected area of the microglial cell. Colocalization is pre-
sented as % of Cy5+ or % of CD68+ positive areas. 150 cells
were analyzed for each experimental condition and time
point. In the case of the in vivo colocalization analysis be-
tween Iba1 and either Cy5 or phospho-Tau staining, three
confocal stacks of images were obtained under a 40X mag-
nification objective in the DG per mouse or per human tis-
sue, respectively. Images were subjected to an invariant
threshold for each of the channels (Cy5 and Iba1), and
Mander’s coefficients were calculated.
- Quantifications relative to microglial cells in human
brain. The number of microglial cells was quantified as
previously described [28]. Briefly, microglial (Iba1+) cells
were counted under a LSM710 Zeiss confocal microscope
(63× Oil immersion objective) using the physical dissector
method adapted for confocal microscopy [28]. Stacks of
images (Z-interval: 1 μm) were obtained and the number
of microglial cells was calculated and then divided by the
reference volume of the stack. Cell counts are presented
as cell density (number of cells/μm3). The area of the nu-
cleus was measured in the image in which the nucleus
showed the maximal profile using ImageJ software. The
number of phagocytic pouches [30] per cell was quantified
in all the cells present in each stack of images, as previ-
ously described [31]. A minimum of 100 cells per patient
were analyzed. Merged images of blue (DAPI) and green
(Iba1) channels were used to distinguish between the nu-
cleus (DAPI staining was prominent) and the phagocytic
pouches (DAPI staining was absent) of microglial cells.
Phosphorylation of tau by GSK-3β
Tau42 and Tau-Cy5 was phosphorylated by GSK-3β
(Sigma, USA) in a buffer containing 25 mM MOPS
pH = 7.2; 12.5 mM glycerol-2-phosphate; 25 mM
MgCl2; 5 mM EGTA; 2 mM EDTA; 0.25 DTT and
5.5 mg of ATP for 60 min at 30 °C, followed by 5 min at
100 °C. The reaction was centrifuged at 14,000 rpm for
10 min at 4 °C, and the supernatant containing
phospho-Tau was collected. The control of the reaction
was performed following the same protocol without
GSK-3β. Tau phosphorylation was corroborated by
western blot.
Affinity chromatography
This method was used to assay the binding between
CX3CR1 and Tau. Affinity chromatography was per-
formed using the protocol described previously [32] with
some modifications as follows: CNBr-activated Sephar-
ose 4B was purchased from Sigma (USA). The medium
was prepared following the manufacturer’s instructions.
One mg of the synthetic peptide containing the CX3CR1
binding site was mixed with 0.3 g of CNBr-activated
Sepharose 4B in a buffer which contained 0.1 M-
NaHCO3, pH 8.5, and 0.5 M-NaCl. The mixture was in-
cubated and gently agitated for 1.5 h at RT, and the
coupling of the peptide to the resin was stopped by the
addition of 0.1 M-Tris, pH 8.0. The resin was washed
and equilibrated with buffer A (0.1 M-Mes (pH 6.4)/
0.5 mM-MgCl2/2 mM-EGTA). One mg of Tau42 protein
dialyzed in buffer A was added to the column. The ex-
clusion volume was collected in aliquots and analyzed
by immunoblotting. The resin was washed and equili-
brated again with buffer A in order to remove the excess
Tau42 that was not bound. The protein bound to the
column was eluted by addition of 0.5 M-NaCl in buffer
A and collected in 250-μl aliquots for analysis. The same
protocol was used to test the binding of CX3CL1 (posi-
tive control), ct-Tau (negative control) and phospho-Tau
to the CX3CR1 peptide bound to the resin. The elution
volume for each peptide was analyzed by
immunoblotting.
To study whether Tau and CX3CL1 compete for bind-
ing to CX3CR1, a competitive assay was performed
using the same protocol as for affinity chromatography.
In this case, Tau (control) or Tau plus CX3CL1 were
added to the column. The elution volume was analyzed
by immunoblotting.
Immunoblotting
The phosphorylation of Tau by GSK3β was determined
by western blotting. An extract of Tau42 was used as a
control. Tau42 without GSK3β was used as a control of
the reaction. Proteins were then separated on 10% so-
dium dodecyl sulfate-polyacrylamide gels before being
transferred electrophoretically onto polyvinylidene
difluoride membranes (GE Healthcare, UK). The mem-
branes were blocked for 2 h with 2% (w/v) skimmed
milk powder in 50 mm Tris-buffered saline, pH 8,
containing 0.05% (v/v) Tween 20 (TBS-Tween), and in-
cubated overnight at 4 °C with rabbit anti-phospho-Tau
(p-S396) antibody (1:1000 dilution). Protein expression
was detected using HRP-conjugated secondary antibody
(1:10,000 dilution). For quantification of immunoreactivity,
images of blots were analyzed using ImageJ Version 1.46r
(National Institutes of Health, Bethesda, MD).
Aliquots obtained from the affinity chromatography
were dotted onto nitrocellulose sheets, blocked with
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0.05% Tween-20 in phosphate-buffered saline (PBS), and
incubated with mouse anti-Tau5 (Calbiochem, USA),
goat anti-CX3CL1 (R&D, USA), mouse anti-Tau46
(Abcam,UK) or rabbit anti-phospho-Tau (p-S396) (Life
Technologies, USA) antibodies (1:1000 dilution in PBS,
containing 0.05% Tween-20) for 2 h at RT. Protein ex-
pression was detected using HRP-conjugated secondary
antibodies (1:10,000 dilution). To measure immunoreac-
tivity, images of blots were analyzed using ImageJ Ver-
sion 1.46r (National Institutes of Health, Bethesda, MD).
The results were presented as the percentage of Tau5
(Tau42), CX3CL1, Tau46 (ct-Tau) and p-S396 (phospho-
Tau) in each fraction relative to the total exclusion
volume.
Statistical analysis
Statistical analysis was performed with GraphPad Prism
software, Version 5.01. Data were tested by one-way
ANOVA. Post-hoc comparisons were analyzed using
Tukey’s test. Differences were considered statistically sig-
nificant when the probability, p, of the null hypothesis
was ≤0.05. Data are presented as the means ± S.E. All in
vitro results were obtained in at least three independent
experiments.
Results
The absence of CX3CR1 specifically decreases the uptake
of tau by microglia
In our previous work, we showed the temporary course
of Tau uptake by wildtype microglia [21]. Following the
same protocol, primary microglia cultures derived from
C57 (WT) and CX3CR1−/− (KO) mice were incubated
with Tau42 labeled with Cy5 (Tau-Cy5), or control PBS-
Cy5 at 1 μM of final concentration for 0, 5, 30 and
60 min. After this time, the presence of internalized Tau
was calculated as percentage of Cy5+ area inside the
microglial cell. Tau-Cy5 (red) was detected, for the first
time, inside microglia (white) of WT mice (Fig. 1a–e)
after 5 min of incubation. However, the Cy5 signal was
absent in KO microglia at the same time point and only
became observable after 60 min of treatment. However,
this signal was reduced in comparison to WT microglia
at this time point (Fig. 1c–e).
In order to elucidate whether the effect of CX3CR1
deletion on the phagocytosis of Tau is specific or
whether it impairs general microglial phagocytic cap-
acity, the internalization of BSA-Cy5 was studied as a
control. Following the same protocol, primary microglia
cultures derived from WT and KO mice were incubated
with 1 μM BSA-Cy5 for 0, 5, 30 and 60 min. After this
time, internalized BSA was calculated as percentage of
Cy5+ area inside the microglial cell (Fig. 1f ). There were
no differences in the amount of BSA detected in cells at
any time tested. The results indicated that CX3CR1
deletion did not affect the general phagocytic capacity of
microglia and further confirmed that CX3CR1 is a spe-
cific receptor involved in Tau phagocytosis by microglia.
Microglia activation is impaired in KO mice
Since the activation of microglia increases the phagocyt-
osis of these cells [7] and we observed an impairment of
Tau internalization by KO microglia, we studied whether
the microglia derived from WTand KO mice are activated
equally by the presence of Tau. In this regard, the CD68
signal was used as a measurement of microglial activation
[30, 33]. WT (Fig. 1g and h) and KO (Fig. 1i and j) micro-
glia were incubated with PBS-Cy5 or Tau-Cy5. The micro-
glial activation rate was quantified as the percentage of
CD68+ (white) area inside the microglial cell (stained with
Iba1, green). In WT microglia, incubation with Tau-Cy5
increased the expression of CD68 compared to the PBS-
Cy5 treatment at every time point tested (Fig. 1k). In con-
trast, in KO microglia, CD68 expression remained
unchanged after the treatment with Tau-Cy5. In addition,
the activation level of KO microglia cultured with PBS-
Cy5 was abnormally high compared with WT microglia
under same conditions. These data suggest that KO
microglia showed alterations in their activation state that
could be related to their impaired capacity to be further
activated in the presence of Tau.
The absence of CX3CR1 impairs the internalization of tau
in vivo
As our results suggested that Tau internalization is im-
paired in KO microglia in primary cultures, we next ex-
amined whether microglia take up Tau in vivo. With this
aim, PBS-Cy5 or Tau-Cy5 were stereotaxically injected
into the DG of WT and KO mice. After one week, the
animals were sacrificed and immunohistochemical ana-
lyses were performed. After the injection of Tau-Cy5,
the Cy5 signal (red) was observed in both WT (Fig. 2a-
b) and KO (Fig. 2c-d) mice. Mander’s coefficient was
used as a measurement of colocalization between the
Cy5 signal and Iba1 staining (Fig. 2e). No differences in
colocalization were found in PBS-Cy5-injected animals.
Conversely, colocalization was reduced in Tau-Cy5-
injected animals when KO and WT mice were compared
(Fig. 2e). We next examined the levels of Tau remaining
in the brain as a result of impaired internalization of Tau
by microglia. For this propose, total Cy5 fluorescence
was analyzed in the DG region of WT and KO mice
injected with PBS-Cy5 or Tau-Cy5 (Fig. 2f ). Although
Cy5+ fluorescence was similar in WT and KO mice
injected with PBS-Cy5, the Cy5 signal was markedly
higher in the DG of KO mice injected with Tau-Cy5
than in that of WT animals receiving the same injection
(Fig. 2f ). Thus, we concluded that the absence of
CX3CR1 impaired the internalization of Tau, thus
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possibly resulting in less efficient clearance of this pro-
tein by KO microglia. Interestingly, these results were
consistent with those obtained in vitro.
In order to rule out the effect of early inflammatory
response as a confounding factor, we injected the DG of
a group of WT and KO animals with PBS-Cy5 or Tau-
Cy5, as previously described, and sacrificed these ani-
mals 8 weeks later (Additional file 1). While there was
no difference in Cy5 fluorescence intensity in animals
injected with PBS-Cy5 (Additional file 1: Figure S1 a, c
and e), the Cy5 signal was increased in Tau-Cy5-injected
KO mice compared to Tau-Cy5- injected WT animals
(Additional file 1: Figure S1 b, d and e). This observation
indicates that, 8 weeks after injection, the levels of Tau
were still significantly higher in the DG of KO mice.
These data further support the notion that the impaired
phagocytic capacity of microglia in KO animals has im-
portant long-term consequences for the brain micro-
environment.
Tau protein binds to CX3CR1
Our results showed that CX3CR1 was involved in the in-
ternalization of Tau by microglia. In addition, the activa-
tion of microglia in response to Tau was attenuated in
KO compared to WT microglia. Therefore, we addressed
whether Tau serves as a ligand of CX3CR1 and whether
Fig. 1 The absence of CX3CR1 leads to a decrease in extracellular Tau internalization by microglia in vitro. Representative immunofluorescence images
of primary cultures of microglia derived from WT mice (a) and their high-power magnification (b), and from KO animals (c) and their magnification
image (d). Cells were incubated with 1 μM Tau-Cy5. Immunofluorescence images for Iba1 (white) and Cy5 (red) are shown separately. (e) Quantification
of Cy5+ area in individual microglial cells treated with either Tau-Cy5, or BSA-Cy5 (f) for 0, 5, 30 and 60 min. g-l Representative images of primary
microglia cultures from WT mice treated with PBS-Cy5 (g) or Tau-Cy5 (h) and from KO animals treated with PBS-Cy5 (i) or Tau-Cy5 (j)
showing CD68 (white) and Iba1 (green) staining. k Quantification of CD68+ area in individual WT and KO microglia after treatment with
PBS or Tau at 0 and 30 min. Bars show means ± S.E. ∗∗∗p ≤ 0.001. White scale bar: 100 μm, purple scale bar: 50 μm
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it can bind to this receptor. To this end, we first per-
formed affinity chromatography studies with the syn-
thetic receptor CX3CR1 coupled to CN-sepharose (Fig.
3a-d). The exclusion volume of each peptide was col-
lected, and the column was washed as described in
Methods section. Next, 0.5 M NaCl in column buffer
was used to elute the proteins bound to CX3CR1. Sev-
eral 25-μl aliquots containing the bound proteins were
collected, and the amount of protein was quantified by
immunoblotting. Purified Tau, detected with a Tau5 anti-
body, was retained in the column (Fig. 3a). CX3CL1, the
natural ligand of CX3CR1 used as a positive control for
the experiment, was also retained in the column (Fig.
3b). CX3CL1 and Tau share 37% identity in some amino
acid sequences (Additional file 1: Figure S2). These se-
quences have a high number of positively charged amino
acids like K, R and H. This composition could explain
why Tau and CX3CL1 bind to CX3CR1. In contrast, the
C-terminal fragment of Tau holds negatively charge
amino acids like D and E. Therefore, we used the C-
terminal fragment of Tau as a negative control. This
fragment, detected by the Tau46 antibody, was not
retained in the column (Fig. 3c), thereby indicating that
it was not able to bind to CX3CR1. Finally, given the
pathologic relevance of phospho-Tau in AD, we exam-
ined whether it can bind to CX3CR1. Tau was phosphor-
ylated by GSK-3β, as described in the Methods section.
First, using western blot, we confirmed that Tau was
phosphorylated after the enzymatic assay with GSK-3β
(Additional file 1: Figure S3). We then performed the
chromatography assay with phospho-Tau following the
same protocol. Phospho-Tau, detected by the p-S396
antibody, was retained in the column (Fig. 3d). These
results suggested that Tau bound to CX3CR1 regard-
less of its phosphorylation state. However, the profile
shown in Fig. 3d suggested that the binding of
phospho-Tau to CX3CR1 was weaker than that shown
by Tau (Fig. 3a) since the former eluted earlier than
the latter (fraction number 1 compared to fraction
number 4).
To determine how critical CX3CR1 was for the bind-
ing of Tau to microglia, microglia cultures from WT
(Fig. 4a) and KO (Fig. 4b) mice were incubated with
Tau-Cy5 at 4 °C for 5 min. The level of Tau on the
microglial surface was measured (Fig. 4c). There was
more Tau attached to the microglial surface in WT than
in KO animals, which indicated that CX3CR1 also con-
tributes to the binding of Tau to this surface.
Fig. 2 The absence of CX3CR1 leads to a decrease in Tau internalization by microglia in vivo. Representative images of the dentate gyrus (DG) of
WT (a-b) and KO mice (c-d) stereotaxically injected with PBS-Cy5 or Tau-Cy5 and sacrificed one week later. Immunofluorescence images for Iba1
(green) and Cy5 (red) and high-power magnification are shown separately. e Colocalization between Iba1 and Cy5 in mice injected with PBS-Cy5
or Tau-Cy5 in the DG. Reduced colocalization between Cy5 and Iba1 can be observed in KO animals injected with Tau-Cy5 in comparison to WT
mice that received the same injection. f Quantification of Cy5 fluorescence intensity in mice injected with PBS-Cy5 or Tau-Cy5. An increased level
of Cy5 fluorescence intensity can be observed in KO mice injected with Tau-Cy5 in comparison to WT mice that received the same injection. Bars
show means ± S.E. ∗p ≤ 0.05; ∗∗p ≤ 0.01; + 0.05 < p ≤ 0.1. Purple scale bar: 100 μm, Blue scale bar: 50 μm. GL, granule layer; H, hilus; ML, molecular
layer; CA3, cornu ammonis region 3; DG, dentate gyrus
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Tau competes with CX3CL1 for binding to CX3CR1
Given that CX3CL1 is the natural ligand of CX3CR1, we
next studied whether CX3CL1 and Tau compete to bind
CX3CR1. To this end, affinity chromatography was used
to determine the amount of Tau retained in the column
in the absence or presence of CX3CL1. The amount of
Tau protein was quantified in the aliquots of eluted
medium by immunoblotting. The binding of Tau to
CX3CR1 was weaker in the presence of CX3CL1 (Fig. 4b).
As shown, Tau eluted earlier in the presence of CX3CL1
(fractions 4–9) than in its absence (fractions 7–10).
Subsequently, in order to study whether the competi-
tion between Tau and CX3CL1 had an effect on Tau in-
ternalization, we addressed whether Tau internalization
by microglia was affected by the presence of CX3CL1 in
vitro. For this purpose, primary microglia cultures were
treated with Tau-Cy5 in the absence or presence of
CX3CL1 (Fig. 4c-d), and the internalization of Tau was
measured by Cy5 fluorescence intensity (Fig. 4e). In the
presence of CX3CL1, the internalization of Tau was re-
duced, as shown by the decreased Cy5+ signal (Fig. 4e).
All together, these results reinforce the idea that
CX3CR1 is involved in the internalization of Tau by
microglia through a specific ligand-receptor binding
mechanism.
Phosphorylated tau and phagocytic phenotype of
microglial cells in AD patients
In 1991, Braak and Braak proposed a neuropathological
classification to differentiate Braak-Tau initial (I–II),
intermediate (III–IV), and advanced (V–VI) stages of
AD on the basis of the spread of neurofibrillary tangles
within the brain [34]. However, there is limited quantita-
tive information on the relationship between Braak-Tau
staging and the phagocytic activity of microglia. To ad-
dress this question, both the number of Iba1+ cells
(green) and phospho-Tau staining (white, red arrows)
were quantified in postmortem tissue derived from con-
trol subjects displaying a Braak-Tau stage equal to 0 and
in postmortem tissue from AD patients at different
Braak stages (Fig. 5a-d). Representative images of Braak-
Tau I (Fig. 5a), Braak-Tau III (Fig. 5b), and Braak-Tau VI
(Fig. 5c) and a high-power magnification image of
Braak-Tau VI (Fig. 5d) were shown. First, phospho-Tau
(p-S396) staining was quantified (Fig. 5e). Hippocampal
phospho-tau staining was enhanced as the Braak-Tau
stage increased (Fig. 5a-e). Next, the number of Iba1+
microglial cells (green) was quantified (Fig. 5f ). Braak-
Tau III-IV and Braak-Tau V-VI patients showed a greater
number of cells compared to control subjects. In order
to analyze the interaction between microglial cells and
phospho-Tau in the brains of AD patients, colocalization
between phospho-Tau and Iba1 was measured. The colo-
calization was found to be increased at Braak-Tau stages
V-VI stages (Fig. 5g).
To study whether the expression of CX3CR1 is differ-
entially regulated at the distinct stages of the disease,
CX3CR1 staining was measured (Fig. 5h). CX3CR1 ex-
pression augmented progressively with increased Braak-
Tau stage, thus indicating that the system is plastically
regulated in the brains of AD patients. Although there
was an increase in CX3CR1 with the advance of Braak-
Fig. 3 Tau binds to CX3CR1. Synthetic CX3CR1 was coupled to CNBr-
activated Sepharose4B. Tau detected with anti-Tau5 (a), the positive
control CX3CL1 (b), the negative control c-terminal Tau detected with
anti-Tau46 (c), and Tau phosphorylated by GSK-3β detected with anti-
pTau396 (d) were loaded on the column, as described in the Methods
section. Each protein sample was used at a concentration of 1 mg/ml.
Exclusion volume (excl. Vol.), aliquots corresponding to the column
washed with buffer A, bound proteins eluted by addition of 0.5 M NaCl
(marked with an arrow), and collected fractions (Fract. N°) are shown.
Note that the profiles indicate that Tau, CX3CL1 and phospho-Tau
were bound to the column, whereas the C-terminal fragment of Tau
was not
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Tau stage, the amount of phospho-Tau was also in-
creased. Given that this increase may reflect a failure of
microglia to internalize phospho-Tau, we phosphorylated
Tau-Cy5 with GSK-3β (Additional file 1: Figure S4). We
then measured the internalization of phospho-Tau-Cy5
by microglial cells and compared it to that of the non-
phosphorylated form (Tau-Cy5) (Fig. 5i-j) in vitro. Im-
portantly, the uptake of phospho-Tau-Cy5 by microglia
was lower than that of Tau-Cy5 under the same experi-
mental conditions (Fig. 5j).
Taken together, these results (namely, the increased
levels of phospho-Tau in the presence of an increased
number of microglial cells) may point to impaired micro-
glial phagocytosis at advanced Braak-Tau stages. In this re-
gard, the phagocytic capacity of microglia was measured
by quantifying the number of phagocytic pouches per cell.
These pouches have been defined as a modification of
microglial processes involved in phagocytosis in vivo [30,
31]. Representative images of these structures in the hu-
man brain are shown in Fig. 6a. Interestingly, a decrease
Fig. 4 Tau competes with CX3CL1 for binding to CX3CR1. a-b Representative images of Tau-Cy5 attached to the surface of WT (a) and KO (b)
microglia after treatment with Tau-Cy5 for 5 min at 4 °C. c Quantification of Cy5 fluorescence intensity on the microglial surface. In the absence
of CX3CR1, the levels of Tau-Cy5 on the membrane of microglial cells are markedly reduced. d Tau profile in the competition assay between Tau
and CX3CL1 detected with anti-Tau5. Note that the profiles indicate that the binding of Tau to the column was weaker in the presence of
CX3CL1. e-g In vitro competition assay performed in primary microglial cell culture. Representative images and quantification of Cy5 fluorescence
intensity (red) and Iba1 (green) in cells treated with Tau-Cy5 in the absence (c) or presence (d) of CX3CL1. As shown, Tau internalization is reduced
in the presence of CX3CL1. Bars show means ± S.E. ∗∗∗p ≤ 0.001. White scale bar: 100 μm, purple scale bar: 50 μm
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in the number of phagocytic pouches was observed in
Braak-Tau III-IV and V-VI patients (Fig. 6a). Furthermore,
the area of the nuclei of microglial cells was measured as
an indicator of their activation state. An increase in this
parameter was found in Braak-Tau V-VI patients as com-
pared to control subjects (Fig. 6c). In order to further ex-
plore the function of the CX3CL1/CX3CR1 axis in AD
patients, the expression of CX3CL1 was measured in the
DG of control subjects and AD patients at different
Braak-Tau stages (Fig. 6d). CX3CL1 expression augmented
progressively with increased Braak-Tau stage.
Taken together, these data further support our previ-
ous notion that an uncoupling of microglia activation-
phagocytosis occurs in parallel with the exacerbated
phosphorylation of Tau at advanced stages of the
disease.
Discussion
Microglia are resident immune cells that play a continuous
surveillance role in the CNS [35]. Microglial phagocytosis is
a crucial process both under physiological and pathological
conditions [36]. In fact, genome-wide association studies
Fig. 5 Tau phosphorylation, the number of microglial cells, colocalization between phosphorylated Tau and CX3CR1, and CX3CR1 expression
increase in advanced stages of AD. Representative images of hippocampal tissue derived from AD patients showing microglia (Iba1, green),
phospho-Tau (p-S396, white, red arrow) and DAPI (blue) staining at different stages of the disease: Braak-Tau I (a), Braak-Tau III (b) and Braak-Tau VI
(c). Immunofluorescence images for Iba1- (green) and Tau-labeled structures (white, red arrow) are shown separately. d Representative high-power
magnification image of microglia (green) and phospho-Tau (red) in Braak-Tau stage VI are shown. Orthogonal views are provided to highlight the
colocalization between microglia and phospho-Tau. e Quantification of phospho-Tau fluorescence intensity present in the human hippocampus
in AD. f Quantification of the number of microglia. g Colocalization between Iba1 and phospho-Tau at different stages of the disease. h Quantification
of fluorescence intensity of CX3CR1 in the human hippocampus. (i-j) Representative images and quantification of the Cy5+ area relative to the
internalization of Tau-Cy5 or phospho-Tau-Cy5 by microglia in vitro. Cell density was calculated as number of cells/μm3. Bars show means
± S.E. + p ≤ 0.05; ∗p ≤ 0.05; ∗∗ p ≤ 0.01 and ∗∗∗p ≤ 0.001. Red scale bar: 40 μm. White scale bar: 50 μm
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have recently found genes associated with a higher prob-
ability of developing sporadic AD. Specifically, mutations in
complement receptor 1 (CR1), the triggering receptor
expressed on myeloid cells 2 (TREM2), and cluster of dif-
ferentiation 33 (CD33) can result in reduced activity of the
complement system and decreased phagocytosis [37–39].
These findings suggest that impaired microglial phagocyt-
osis contributes to the progression of the disease. In line
with this, it is known that the CX3CL1/CX3CR1 axis plays
a central role in communication between microglia and
neurons [10]. The present data show that microglia derived
from KO mice show reduced in vitro phagocytosis of Tau
compared to those from WT animals. Moreover, Tau bind-
ing to KO microglia is also reduced, thus suggesting that
this receptor plays a key role not only in Tau internalization
but also in Tau recognition and binding to the membrane.
In line with this, microglia from KO mice showed
a reduced capacity in vivo to phagocytose Tau, as re-
vealed by the decrease in the colocalization between
the Cy5 signal and Iba1 staining. On the basis of
our findings, we propose that the inefficient phago-
cytosis of Tau is detrimental for neighboring cells.
Importantly, a similar hypothesis has recently been
put forward for beta-amyloid [40].
Several studies, including our previous one [21], con-
verge in the pivotal role played by microglia phagocytosis
in the clearance of Tau and thus in preventing the spread
of this protein and the progression of AD [2, 16, 22].
However, the mechanism of Tau clearance remains largely
unknown. In neurodegenerative disorders, disruption of
the CX3CL1-CX3CR1 axis has been described to have
various effects. In studies conducted in KO mice, such dis-
ruption led to contradictory reports indicating either a
protective effect [41] or worsening of the condition [42].
The present study is the first to show that Tau binds dir-
ectly to CX3CR1, thereby contributing to its internaliza-
tion by microglia. Tau shares positively charged amino
acid residues with CX3CL1—a feature that may contribute
to CX3CR1 binding. Additional site-directed mutagenesis
experiments are now required to identify the specific
amino acids involved in the binding of Tau to CX3CR1.
The analysis of brain tissue from AD patients revealed
that an increase in the levels of phospho-Tau, the num-
ber of microglia, and the colocalization between
phospho-Tau and Iba1 occurred in parallel as the disease
advanced. It should be noted that in vivo experiments
allow the study of colocalization but cannot ensure the
internalization of this molecule into Iba1+ cells. We
hypothesize that the amount of phospho-Tau adhered to
the microglial surface increases at advanced stages of
AD. However, given the higher amount of total
phospho-Tau found in the tissue, it is not reasonable to
Fig. 6 The impaired phagocytic capacity of microglia increases in advanced stages of AD. a Representative immunofluorescence images of
phagocytic pouche (yellow arrow) in a microglial cell (Iba1, green) of human AD tissue. b Quantification of the number of phagocytic pouches per
microglial cell. c Quantification of nucleus area of microglia in human tissue. d Quantification of CX3CL1 fluorescence intensity present in the
human hippocampus in AD. Bars show means ± S.E. + p ≤ 0.05; ∗p ≤ 0.05; ∗∗ p ≤ 0.01 and ∗∗∗p ≤ 0.001. Purple scale bar: 40 μm. N, microglia
nucleus (DAPI)
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assume that Tau phagocytosis is also increased, because it
may be impaired at some point of the process. In fact, a de-
crease in the phagocytic activity of these cells was inferred
by the reduction in the number of phagocytic pouches. Sev-
eral authors have proposed that microglia malfunction with
age [43, 44] and that this failure could be related to the de-
velopment of AD. This “senescent” phenotype may include
impaired phagocytic capacity. Our data support the notion
that the uncoupling of microglial activation and phagocyt-
osis occurs at later stages of AD. This is a phenomenon pre-
viously described in other neurodegenerative conditions
[45]. Indeed, it has been proposed that neuron/microglial
crosstalk is impaired in chronic neurodegenerative condi-
tions [15]. This phenomenon may be the consequence of
the chronic maintenance of a pro-inflammatory state
throughout the advance of the disease that leads to system
failure. Alternatively, it may constitute a neuroprotective
mechanism aimed to counteract the excessive production of
pro-inflammatory cytokines by microglia. Although unravel-
ling the drivers of the decreased phagocytic capacity of
microglia in AD is beyond the scope of the present study,
we sought to determine the expression levels of CX3CR1
ligand, namely the neuronal cytokine CX3CL1, at various
Braak-Tau stages. CX3CL1 expression was markedly in-
creased at late stages of AD. This increase may act at two
levels on the phagocytic capacity of microglia. On the one
hand, CX3CL1 is an anti-inflammatory cytokine that retains
microglial cells in a resting state [12]. However, importantly,
on the other hand, our results demonstrate competition be-
tween Tau and CX3CL1 to bind CX3CR1. Whether or not
the increase in CX3CL1 expression drives the impaired
phagocytic capacity of microglia or whether these two phe-
nomena merely occur in parallel in AD patients should be
addressed by future studies. In addition, our in vitro data
provide evidence that the internalization of phospho-Tau by
microglial cells (triggered by its binding to CX3CR1) takes
place in a less efficient manner than for the non-
phosphorylated form of the protein.
Further studies are needed to elucidate whether the
uncoupling of microglial activation and phagocytosis is
due to exacerbated Tau phosphorylation driven by the
increased expression of CX3CL1 or by alternative mech-
anisms. However, our in vitro data provide evidence of a
reduced efficiency of microglia to internalize phospho-
Tau and competition between Tau and the natural
CX3CR1 ligand, CX3CL1, to bind this receptor.
These data reveal a novel mechanism of Tau internaliza-
tion by microglial cells and further support the notion that
the CX3CR1/CX3CL1 axis plays a critical role in the pro-
gression of AD.
Conclusions
In this work we have demonstrated a novel mechanism of
Tau internalization by microglia through the direct binding
to CX3CR1. We have suggested an uncoupling of
activation-phagocytosis of microglia which occurs in paral-
lel with the exacerbated phosphorylation of Tau at ad-
vanced stages of the disease. Finally, CX3CR1/CX3CL1 axis
plays a critical role in the progression of AD.
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